{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:52:52Z","timestamp":1789501972397,"version":"build-2803163510"},"reference-count":44,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T00:00:00Z","timestamp":1252454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To determine the safety, efficacy, and PK profile of intravenous busulfan (Bu) in the context of a Bu and cyclophosphamide (IVBuCy) preparative regimen in children undergoing allogeneic hematopoietic stem cell transplantation (HSCT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty\u2010four children were enrolled in an open\u2010label, multicenter trial of IVBuCy as the preparative regimen for HLA\u2010matched sibling allogeneic HSCT. IVBu was administered q6\u2009hr for 16 doses with a targeted area under the curve (AUC) of 900\u20131,350\u2009\u00b5Mol\u2010min. The initial dose was 0.8\u2009mg\/kg for children &gt;4 years of age and 1\u2009mg\/kg for those &lt;4 years of age. PK of the first dose IVBu was determined to calculate a single dosage adjustment, and with the 9th and 13th doses to confirm steady\u2010state PK.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The targeted AUC was achieved with the first dose in 17\/24 (71%) of the children using the age\u2010adjusted dosing approach. Dosing was increased in five patients, and reduced in two patients to achieve target values. After dose adjustment based on PK, 91% of the children had an AUC within the target range at steady state (AUCss). Median final dosing and clearance (CL) of IVBu were 1.1\u2009mg\/kg and 4.1\u2009ml\/min\/kg in patients \u22644 years, and 0.9\u2009mg\/kg and 2.9\u2009ml\/min\/kg in patients &gt;4 years. All children were engrafted with documented donor chimerism. No late rejections or graft failures occurred. Four patients had veno\u2010occlusive disease, three of which resolved within 2 weeks of onset. Two children died from transplant\u2010related causes unrelated to Bu.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IVBu is a safe and effective and offers the benefit of predictable and consistent systemic exposure. Pediatr Blood Cancer 2010;54:291\u2013298. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.22227","type":"journal-article","created":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T17:52:18Z","timestamp":1252518738000},"page":"291-298","source":"Crossref","is-referenced-by-count":37,"title":["Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1002","volume":"54","author":[{"given":"Donna A.","family":"Wall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Wah","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Nieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Yeager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Przepiorka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Mezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Kletzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,9,9]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"225","article-title":"Association of busulfan area under the curve with veno\u2010occlusive disease following BMT","volume":"17","author":"Dix SP","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00694339"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700994"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703264"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200709040-00008"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181621cde"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood.V75.8.1723.1723","article-title":"Busulfan disposition in children","volume":"75","author":"Grochow LB","year":"1990","journal-title":"Blood"},{"key":"e_1_2_6_9_2","first-page":"843","article-title":"Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders","volume":"18","author":"Hassan M","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00689702"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558081"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257448"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702371"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050404"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702351"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(00)70064-4"},{"key":"e_1_2_6_17_2","first-page":"31","article-title":"Graft\u2010rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery JT","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198712000-00011"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197410000-00001"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780140404"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.296"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-0436.1979.tb01034.x"},{"key":"e_1_2_6_23_2","first-page":"1113","article-title":"Early decrease in hyaluronidase\u2010sensitive cell surface charge during the differentiation of Friend erythroleukemic cells by dimethyl sulfoxide","volume":"39","author":"Sato C","year":"1979","journal-title":"Cancer Res"},{"key":"e_1_2_6_24_2","first-page":"477","article-title":"A Phase I study of dimethylacetamide","volume":"16","author":"Weiss AJ","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_6_25_2","first-page":"835","article-title":"Phase I trial of PCNU administered by 5\u2010day courses","volume":"65","author":"Earhart RH","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood.V79.9.2475.2475","article-title":"Is 600 mg\/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?","volume":"79","author":"Vassal G","year":"1992","journal-title":"Blood"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00688324"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12374452"},{"key":"e_1_2_6_29_2","first-page":"467","article-title":"Hepatic veno\u2010occlusive disease post\u2010bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: Incidence, risk factors, and clinical outcome","volume":"7","author":"Ozkaynak MF","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood.V84.7.2357.2357","article-title":"Busulfan pharmacokinetics using a single daily high\u2010dose regimen in children with acute leukemia","volume":"84","author":"Shaw PJ","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood.V80.9.2425.2425","article-title":"Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation","volume":"80","author":"Yeager AM","year":"1992","journal-title":"Blood"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006295789"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0455-2"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704446"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.abbmt080619"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702700"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035092"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2390"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199810000-00017"},{"key":"e_1_2_6_40_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bmt.1702561","article-title":"Individualizing high\u2010dose oral busulfan: Prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies","volume":"26","author":"Tran HT","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704209"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1856"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2619"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.437"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0982-4"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22227","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T19:24:47Z","timestamp":1696879487000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,9]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1002\/pbc.22227"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22227","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,9]]}}}